Drug Trial Radar · NCT03399786
Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Last checked: Nov 20, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Jan 18, 2018
Primary completion
Jun 10, 2019
Study completion Mar 17, 2020
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jan 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by evinacumab intravenously (IV) in comparison to placebo after 24 weeks in patients with homozygous familial hypercholesterolemia (HoFH). The secondary objectives of the study are to evaluate the effect of evinacumab IV on other lipid parameters, evaluate the effect of evinacumab on LDL-C goal attainment, assess the effect of evinacumab on eligibility for apheresis (using German and US apheresis criteria), evaluate the safety and tolerability of evinacumab in patients with HoFH, assess the pharmacokinetics (PK) of evinacumab in patients with HoFH and evaluate the potential development of anti-evinacumab antibodies.
Conditions
- Homozygous Familial Hypercholesterolemia
Interventions
evinacumabDrug
IV administration of evinacumab
PlaceboDrug
IV administration of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand)Time frame: Week 24
Locations
30 sites in 11 countries. Site status is shown where the registry gives one.
Regeneron Research Site
Boca Raton, Florida
Regeneron Research Site
Boston, Massachusetts
Regeneron Research Site
New York, New York
Regeneron Research Site
Cincinnati, Ohio
Regeneron Research Site
Portland, Oregon
Regeneron Research Site
Dallas, Texas
Regeneron Research Site
Camperdown, New South Wales, Australia
Regeneron Research Site
Perth, Western Australia, Australia
Regeneron Research Site
Innsbruck, Austria
Regeneron Research Site
Chicoutimi, Quebec, Canada
Regeneron Research Site
Québec, Quebec, Canada
Regeneron Research Site
Marseille, France
Regeneron Research Site
Paris, Cedex, France
Regeneron Research Site
Athens, Greece
Regeneron Research Site
Ioannina, Ioannina, Greece
Regeneron Research Site # 2
Naples, Italy
Regeneron Research Site
Osaka, Japan
Regeneron Research Site
Kurume, Fukuoka, Japan
Regeneron Research Site
Nishinomiya, Hyōgo, Japan
Regeneron Research Site
Kanazawa, Ishikawa-ken, Japan
Regeneron Research Site #3
Suita, Osaka, Japan
Regeneron Research Site
Suita, Osaka, Japan
Regeneron Research Site
Amsterdam, Netherlands
Regeneron Research Site
Rotterdam, Netherlands
Regeneron Research Site
Parktown, Johannesburg, South Africa
Regeneron Research Site
Ivano-Frankivsk, Ukraine
Regeneron Research Site
Kharkiv, Ukraine
Regeneron Research Site #2
Kharkiv, Ukraine
Regeneron Research Site #2
Kyiv, Ukraine
Regeneron Research Site
Kyiv, Ukraine
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.